We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.
More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.
The SITC Combination Immunotherapies Task Force has convened to:
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
Patrick Ott, MD, PhD Dana-Farber Cancer Institute/Harvard Medical School
[Holbrook E. Kohrt, MD, PhD*] Stanford Cancer Institute
F. Stephen Hodi, MD Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS Rutgers Cancer Institute of New Jersey
Drew M. Pardoll, MD, PhD Johns Hopkins University School of Medicine
Jon M. Wigginton, MD MacroGenics, Inc.
Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center
*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016) Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
This may be due to an alternate immune checkpoint, CD200 (OX2) checkpoint blockade. The immuneosuppressive CD200 protein shuts down the immune system through multiple mechanisms (Xiong et al, 2016). We demonstrated that human glioblastoma in the top ...
While I agree with Stephanie's detailed account, simply put checkpoint molecules are a signature of exhausted/ chronically stimulated lymphocytes and therefore serves as a feedback mechanism to mitigate the immune activation from entering an overdrive ...
Hi Stephanie many thanks for your ample reply. It makes sense indeed in order to secure self-antigens. However, is immune system evasion by means of immune checkpoint a matter of quality or quantity? I mean is there a cutoff for "normal"CTLA4, PD1 levels ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org